专利检索_ .产生3'磷酸单酯的核糖核酸内切酶专利检索_ .产生3'磷酸单酯的核糖核酸内切酶专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
101	新規タンパク質素材	JP2014527849	2012-07-31	JPWO2014020676A1	2016-07-11	愛子大町; 松山　博昭; 博昭松山; 森田　如一; 如一森田; 祐子石田; 貴幸奈良; 加藤　健; 健加藤; 芹澤　篤; 篤芹澤
安全で、日常的に摂取することにより、骨粗鬆症や骨折、リウマチ、関節炎などの種々の骨疾患の予防や治療に有用である新規タンパク質素材を提供することを課題とする。また、本発明は、経口摂取により骨粗鬆症や骨折、リウマチ、関節炎などの種々の骨疾患の予防や治療に有用である骨強化用飲食品又は飼料を提供することを課題とする。アンジオジェニン及び/又はアンジオジェニン分解物を2〜15mg/100mg含有し、かつ、ラクトパーオキシダーゼ及び/又はラクトパーオキシダーゼ分解物を、アンジオジェニン及び/又はアンジオジェニン分解物に対して、質量比0.3〜20の範囲で含有するタンパク質素材。このようなタンパク質素材を摂取することにより、骨を強化、特に骨粗鬆症や骨折、リウマチ、関節炎などの種々の骨疾患を予防ならびに治療することができる。
102	抗菌活性増強剤	JP2013526635	2011-07-29	JP5699216B2	2015-04-08	村田麻衣; 若林裕之; 山内恒治

103	疾患及び障害を治療するためのアンギオゲニン又はアンギオゲニンアゴニストの使用	JP2011508769	2009-05-14	JP5646459B2	2014-12-24	マクドナギ，マシュー; コクッス，ベンジャミン; テスター，アンガス; ホブマン，ピーター

104	How to promote the healing of damage and disorders of the connective tissue	JP2013548446	2012-01-07	JP2014501778A	2014-01-23	シング，ジョージ，エル．; スティード，デーヴィッド，エル．
本発明は、結合組織の損傷および障害の治癒を促進する方法に向けられている。特に本発明は、腱および靭帯の損傷および障害の治癒の促進に向けられている。かかる方法は、非限定的に、胚外サイトカイン分泌細胞(本明細書中でECS細胞と称される)、例えば、非限定的に、羊膜由来多能性前駆細胞(本明細書中でAMP細胞と称される)およびそれに由来するならし培地(本明細書中で羊膜由来細胞性サイトカイン溶液またはACCSと称される)、例えばプールされたACCS、および生理的サイトカイン溶液(PCS)を含む新規組成物を利用する。【選択図】なし
105	Use of angiogenin or angiogenin agonist for the treatment of diseases and disorders	JP2011508769	2009-05-14	JP2011519961A	2011-07-14	コクッス，ベンジャミン; テスター，アンガス; ホブマン，ピーター; マクドナギ，マシュー
本発明は、ミオスタチンの増加若しくは調節不全を特徴とする障害、フォリスタチンとアンギオゲニンとの相互作用を利用して組織機能を改善することができる障害、神経疾患若しくは障害、脊髄傷害若しくは疾患、骨疾患若しくは障害、グルコース恒常性が関与する疾患の各治療、創傷治癒、神経保護、神経系の機能補助又は代謝性疾患の管理のための方法であって、有効量のアンギオゲニン又はアンギオゲニンアゴニストを投与することを含む方法を提供する。アンギオゲニンを含む組成物及び栄養補助食品も提供する。【選択図】図２
106	BEVERAGE, AND METHOD FOR PRODUCING SAME	EP12882432	2012-07-31	EP2880998A4	2016-01-20	OHMACHI AIKO; MATSUYAMA HIROAKI; MORITA YOSHIKAZU; ISHIDA YUKO; NARA TAKAYUKI; KATO KEN; SERIZAWA ATSUSHI; UENO HIROSHI; URAZONO HIROSHI
The invention relates to a drink includes angiogenin and/or angiogenin hydrolysate in an amount of more than 0.8 mg/100 ml and not more than 150 mg/100 ml, and cystatin and/or cystatin hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.006 to 1.7.
107	FERMENTED MILK PRODUCT, AND METHOD FOR PRODUCING SAME	EP12882143	2012-07-31	EP2880982A4	2016-01-20	OHMACHI AIKO; MATSUYAMA HIROAKI; MORITA YOSHIKAZU; ISHIDA YUKO; NARA TAKAYUKI; KATO KEN; SERIZAWA ATSUSHI; UENO HIROSHI; URAZONO HIROSHI
The invention relates to provide a fermented milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 0.9 mg/100 g to 150 mg/100 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 23.
108	FERMENTED MILK PRODUCT, AND METHOD FOR PRODUCING SAME	EP12882093	2012-07-31	EP2880981A4	2016-01-13	OHMACHI AIKO; MATSUYAMA HIROAKI; MORITA YOSHIKAZU; ISHIDA YUKO; NARA TAKAYUKI; KATO KEN; SERIZAWA ATSUSHI; UENO HIROSHI; URAZONO HIROSHI
The invention relates to a fermented milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 0.9 mg/100 g to 150 mg/100 g, and cystatin and/or cystatin hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.006 to 1.7.
109	MULTIMERIC COMPLEXES WITH IMPROVED IN VIVO STABILITY, PHARMACOKINETICS AND EFFICACY	EP13797550	2013-05-24	EP2854845A4	2015-11-18	ROSSI EDMUND A; CHANG CHIEN-HSING; GOLDENBERG DAVID M
The present invention concerns multimeric complexes based on antibody fusion proteins comprising an AD moiety attached to the C-terminal end of each antibody light chain. The complexes further comprise effector moities attached to DDD moieties. Two copies of the DDD moiety form a dimer that binds to the AD moiety. The complexes may be trimers, pentamers, hexamers or other multimers. The effector moieties may be selected from a second antibody or antigen-binding fragment thereof, a cytokine, an interferon, a toxin, an antigen, a xenoantigen, a hapten, a protamine, a hormone, an enzyme, a ligand-binding protein, a pro-apoptotic agent and an anti-angiogenic agent. Surprisingly, attachment of the AD moiety to the C-terminal end of the antibody light chain results in improved pharmacokinetics and in vivo stability and efficacy, compared to homologous complexes wherein the AD moiety is attached to the antibody heavy chain.
110	BEVERAGE, AND METHOD FOR PRODUCING SAME	EP12882432.3	2012-07-31	EP2880998A1	2015-06-10	OHMACHI, Aiko; MATSUYAMA, Hiroaki; MORITA, Yoshikazu; ISHIDA, Yuko; NARA, Takayuki; KATO, Ken; SERIZAWA, Atsushi; UENO, Hiroshi; URAZONO, Hiroshi
The invention relates to a drink includes angiogenin and/or angiogenin hydrolysate in an amount of more than 0.8 mg/100 ml and not more than 150 mg/100 ml, and cystatin and/or cystatin hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.006 to 1.7.
111	CHEESE PRODUCT, AND METHOD FOR PRODUCING SAME	EP12882366.3	2012-07-31	EP2880987A1	2015-06-10	OHMACHI, Aiko; MATSUYAMA, Hiroaki; MORITA, Yoshikazu; ISHIDA, Yuko; NARA, Takayuki; KATO, Ken; SERIZAWA, Atsushi; UENO, Hiroshi; URAZONO, Hiroshi
The invention relates to a cheese includes angiogenin and/or angiogenin hydrolysate in an amount of 6.5 mg/100 g to 160 mg/100 g, and cystatin and/or cystatin hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.02 to 1.6.
112	CHEESE AND METHOD FOR PRODUCING SAME	EP12882348.1	2012-07-31	EP2880986A1	2015-06-10	OHMACHI, Aiko; MATSUYAMA, Hiroaki; MORITA, Yoshikazu; ISHIDA, Yuko; NARA, Takayuki; KATO, Ken; SERIZAWA, Atsushi; UENO, Hiroshi; URAZONO, Hiroshi
The invention relates to a cheese includes angiogenin and/or angiogenin hydrolysate in an amount of 6.5 mg/100 g to 160 mg/100 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 33.
113	IN SILICO AFFINITY MATURATION	EP12837610.0	2012-12-18	EP2795499A2	2014-10-29	OBERLIN, Michael; KROEMER, Romano; MIKOL, Vincent; MINOUX, Hervé; BAURIN, Nicolas
Methods are disclosed for increasing the binding affinity of binding proteins using in silico affinity maturation.
114	METHODS FOR CONTROL OF FLUX IN METABOLIC PATHWAYS	EP09836804.6	2009-12-14	EP2376619A1	2011-10-19	KLEIN-MARCUSCHAMER, Daniel
The invention pertains to a method for preparing cells that can be used as biocatalysts by inducing in them a growth-decoupled state, in which interferase inhibits the expression of genes except the ones that code for the pathway enzymes of interest. mRNAs that code for interferase-resistant products are overexpressed in the background of a metabolically-frozen cell. Enzymes that compete for a substrate or product of the pathway of interest may be altered such that the enzyme is sensitive to a site-specific protease, which protease is inducible in the host cell.
115	USE OF ANGIOGENIN OR ANGIOGENIN AGONISTS FOR TREATING DISEASES AND DISORDERS	EP09745302	2009-05-14	EP2303311A4	2011-10-05	MCDONAGH MATTHEW; COCKS BENJAMIN; TESTER ANGUS; HOBMAN PETER
The invention provides a method of treating a disorder characterized by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuroprotection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.
116	ANGIOGENIN AND VARIANTS THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISEASES	PCT/US2010055233	2010-11-03	WO2011062762A2	2011-05-26	HU GUO-FU; KISHIKAWA HIROKO
Methods and compositions for treating neurodegenerative disorders using angiogenin and/or angiogenin variants are provided.
117	ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF	US15981762	2018-05-16	US20180271938A1	2018-09-27	Stephane Bancel; Jason P. Schrum; Alexander Aristarkhov
Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of microorganisms. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent microbial infection, or to improve a subject's heath or wellbeing.
118	NOVEL PROTEIN MATERIAL	US15684175	2017-08-23	US20170348399A1	2017-12-07	Aiko OHMACHI; Hiroaki MATSUYAMA; Yoshikazu MORITA; Yuko ISHIDA; Takayuki NARA; Ken KATO; Atsushi SERIZAWA
The invention relates to a protein material includes angiogenin and/or angiogenin hydrolysate in an amount of 2 to 15 mg/100 mg, and lactoperoxidase and/or lactoperoxidase hydrolysate, in the mass ratio to angiogenin and/or angiogenin hydrolysate of 0.3 to 20.
119	NOVEL POWDERED MILK PRODUCT AND METHOD FOR PRODUCING THE SAME	US15656099	2017-07-21	US20170319666A1	2017-11-09	Aiko OHMACHI; Hiroaki MATSUYAMA; Yoshikazu MORITA; Yuko ISHIDA; Takayuki NARA; Ken KATO; Atsushi SERIZAWA; Hiroshi UENO; Hiroshi URAZONO
The invention relates to a powdered milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 1.4 to 24 mg/15 g, and cystatin and/or cystatin hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.03 to 1.3.
120	BEVERAGE, AND METHOD OF PRODUCING THE SAME	US15640977	2017-07-03	US20170296632A1	2017-10-19	Aiko OHMACHI; Hiroaki MATSUYAMA; Yoshikazu MORITA; Yuko ISHIDA; Takayuki NARA; Ken KATO; Atsushi SERIZAWA; Hiroshi UENO; Hiroshi URAZONO
The invention relates to a drink includes angiogenin and/or angiogenin hydrolysate in an amount of more than 0.8 mg/100 ml and not more than 150 mg/100 ml, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 23.

1 2 3 4 5 6 7 8 9 10

该功能需要专业版企业版VIP权限，您可以：